Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 1997
[Sickle cell anemia in children: value of hydroxyurea in severe forms].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oury A P, Hoyoux C, Dresse M F, Chantraine J M
Аннотация
BACKGROUND: Sickling of red cells in patients with sickle cell anemia causes painful vaso-occlusive crises (VOC). Hydroxyurea (HU) has been shown to increase HbF production and therefore has the potential to prevent these crises in adult patients. This work aimed to confirm its clinical efficiency in children.
PATIENTS AND METHODS: Since 1993, eight children and adolescents (5-16 years old) with hemoglobinopathy (HbS > 65%) were given HU (14 to 27 mg/kg/day) for a mean duration of 10 months. We did a retrospective study about different data, especially inpatient days for VOC, pain intensity during these crises, individual transfusion requirements and HbF level.
RESULTS: As the HbF levels increased, we observed a reduction of the inpatient days for VOC, of the pain intensity during these crises and of the mean number of units transfused per month.
CONCLUSION: HU is the first clinically acceptable drug shown to prevent painful crises in adults but also in children with sickle cell anemia. However, its effects and potential toxicity are still unknown and the other therapeutic possibilities have to be considered before starting a long-term treatment with HU.
PATIENTS AND METHODS: Since 1993, eight children and adolescents (5-16 years old) with hemoglobinopathy (HbS > 65%) were given HU (14 to 27 mg/kg/day) for a mean duration of 10 months. We did a retrospective study about different data, especially inpatient days for VOC, pain intensity during these crises, individual transfusion requirements and HbF level.
RESULTS: As the HbF levels increased, we observed a reduction of the inpatient days for VOC, of the pain intensity during these crises and of the mean number of units transfused per month.
CONCLUSION: HU is the first clinically acceptable drug shown to prevent painful crises in adults but also in children with sickle cell anemia. However, its effects and potential toxicity are still unknown and the other therapeutic possibilities have to be considered before starting a long-term treatment with HU.